Rockefeller Capital Management
ENTA icon

Rockefeller Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Rockefeller Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.4K Buy
2,563
+2,049
+399% +$27.5K ﹤0.01% 3483
2025
Q4 		$8.11K Buy
+514
New +$6.53K ﹤0.01% 3898
2019
Q2 		– Sell
-21
Closed -$2K – 1744
2019
Q1 		$2K Buy
+21
New +$1.88K ﹤0.01% 1781

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Rockefeller Capital Management's ENTA Position: Q1 2026 in Review

Rockefeller Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 399% in Q1 2026, buying an estimated $27.5K and bringing the position to 2,563 shares worth $32.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3483.

Rockefeller Capital Management first reported a position in ENTA in Q1 2019 and has held it in 3 quarters since. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Rockefeller Capital Management held 2,563 shares of Enanta Pharmaceuticals worth $32.4K as of Q1 2026.
  • Rockefeller Capital Management bought 2,049 Enanta Pharmaceuticals shares in Q1 2026, an estimated $27.5K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3483 holding.
  • Rockefeller Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2019 and has held it in 3 quarters since.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.